DE69214588T2 - Methanoanthracene als Dopaminantagonisten - Google Patents

Methanoanthracene als Dopaminantagonisten

Info

Publication number
DE69214588T2
DE69214588T2 DE69214588T DE69214588T DE69214588T2 DE 69214588 T2 DE69214588 T2 DE 69214588T2 DE 69214588 T DE69214588 T DE 69214588T DE 69214588 T DE69214588 T DE 69214588T DE 69214588 T2 DE69214588 T2 DE 69214588T2
Authority
DE
Germany
Prior art keywords
dihydro
methanoanthracen
ylmethyl
piperidin
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69214588T
Other languages
German (de)
English (en)
Other versions
DE69214588D1 (de
Inventor
Robert Toms Jacobs
Michael Thaddeus Klimas
Cyrus John Ohnmacht
Marc Ornal Terpko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of DE69214588D1 publication Critical patent/DE69214588D1/de
Publication of DE69214588T2 publication Critical patent/DE69214588T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69214588T 1991-08-15 1992-08-11 Methanoanthracene als Dopaminantagonisten Expired - Lifetime DE69214588T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919117639A GB9117639D0 (en) 1991-08-15 1991-08-15 Therapeutic compounds

Publications (2)

Publication Number Publication Date
DE69214588D1 DE69214588D1 (de) 1996-11-21
DE69214588T2 true DE69214588T2 (de) 1997-05-28

Family

ID=10700033

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69214588T Expired - Lifetime DE69214588T2 (de) 1991-08-15 1992-08-11 Methanoanthracene als Dopaminantagonisten

Country Status (25)

Country Link
EP (1) EP0533344B1 (enExample)
JP (1) JP2889056B2 (enExample)
KR (1) KR100245955B1 (enExample)
AT (1) ATE144253T1 (enExample)
AU (1) AU658905B2 (enExample)
BG (1) BG61893B2 (enExample)
CA (1) CA2076191A1 (enExample)
CZ (1) CZ283848B6 (enExample)
DE (1) DE69214588T2 (enExample)
DK (1) DK0533344T3 (enExample)
ES (1) ES2092646T3 (enExample)
FI (1) FI102964B (enExample)
GB (2) GB9117639D0 (enExample)
GR (1) GR3021398T3 (enExample)
HK (1) HK83697A (enExample)
HU (2) HUT66625A (enExample)
IE (1) IE922588A1 (enExample)
IL (1) IL102807A (enExample)
NO (1) NO301008B1 (enExample)
NZ (1) NZ243955A (enExample)
RU (1) RU2099328C1 (enExample)
SG (1) SG48140A1 (enExample)
SK (1) SK280356B6 (enExample)
TW (1) TW221808B (enExample)
ZA (1) ZA926148B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314250D0 (en) * 1993-07-09 1993-08-18 Zeneca Ltd Piperidinyl compounds
GB9216298D0 (en) * 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
GB9216297D0 (en) * 1991-08-15 1992-09-16 Ici Plc Therapeutic agents
CA2181759A1 (en) * 1995-07-26 1997-01-27 Mira A. Kanzelberger (thiophen-2-yl)-piperidin or tetrahydropyridin azabicyclocarboxamides
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5911576B2 (ja) * 1975-07-07 1984-03-16 住友化学工業株式会社 新規なメタノ−アントラセン誘導体の製造法
US4358620A (en) * 1974-12-13 1982-11-09 Sumitomo Chemical Company, Limited 9-Formyl-9,10-dihydro-9,10-methanoanthracene
GB1508669A (en) * 1974-12-13 1978-04-26 Sumitomo Chemical Co Methanoanthracene derivative and a process for the preparation thereof
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
JPS5910654B2 (ja) * 1976-04-07 1984-03-10 住友化学工業株式会社 新規なメタノ−アントラセン誘導体

Also Published As

Publication number Publication date
HUT66625A (en) 1994-12-28
IL102807A0 (en) 1993-01-31
EP0533344A1 (en) 1993-03-24
FI923663A7 (fi) 1993-02-16
SK251992A3 (en) 1999-12-10
CA2076191A1 (en) 1993-02-16
NO923199L (no) 1993-02-16
GB9216296D0 (en) 1992-09-16
JPH05213872A (ja) 1993-08-24
NO923199D0 (no) 1992-08-14
CZ283848B6 (cs) 1998-06-17
TW221808B (enExample) 1994-03-21
NO301008B1 (no) 1997-09-01
AU2101492A (en) 1993-02-18
RU2099328C1 (ru) 1997-12-20
ES2092646T3 (es) 1996-12-01
EP0533344B1 (en) 1996-10-16
HK83697A (en) 1997-06-27
KR100245955B1 (ko) 2000-04-01
NZ243955A (en) 1995-10-26
FI923663A0 (fi) 1992-08-14
KR930004262A (ko) 1993-03-22
GR3021398T3 (en) 1997-01-31
ATE144253T1 (de) 1996-11-15
HU211661A9 (en) 1995-12-28
IE922588A1 (en) 1993-02-24
JP2889056B2 (ja) 1999-05-10
ZA926148B (en) 1993-04-28
DE69214588D1 (de) 1996-11-21
IL102807A (en) 1998-08-16
GB9117639D0 (en) 1991-10-02
BG61893B2 (bg) 1998-08-31
AU658905B2 (en) 1995-05-04
FI102964B1 (fi) 1999-03-31
FI102964B (fi) 1999-03-31
HU9202643D0 (en) 1992-10-28
SK280356B6 (sk) 1999-12-10
SG48140A1 (en) 1998-04-17
CZ251992A3 (en) 1993-02-17
DK0533344T3 (enExample) 1997-03-03

Similar Documents

Publication Publication Date Title
DE69031649T2 (de) Oxoindolderivate
DE69929704T2 (de) Tetrahydrobenzazepin-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
DE69031075T2 (de) 5-(1-aminocyclohexyl)-2(1h)-pyridinon und verwandte verbindungen
DE60309852T2 (de) Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
EP0533344B1 (en) Methanoanthracenes as dopamine antagonists
DE69214587T2 (de) Methanoanthracene als Dopaminantagonisten
DE69733427T2 (de) Tetrahydrobezindol derivate
DE68905845T2 (de) Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
WO1996005837A1 (de) Verwendung von n-substituierten phenothiazinen
US5681840A (en) Tricyclic antipsychotic compounds
EP0409048B1 (de) Aminoalkylsubstituierte 2-Aminothiazole und diese enthaltende therapeutische Mittel
DE69214586T2 (de) Methanoanthracene als Dopaminantagonisten
DE69303605T2 (de) Unverbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
DE69227207T2 (de) 1-Piperazinyl-2-butene und 2-butyne, Zwischenverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0389425B1 (de) Neue Benzothiopyranylamine
DE2706859A1 (de) Thiazinderivate
DE69128845T2 (de) 4-[3-(4-Oxothiazoldinyl)]butynylamine, Verfahren zu deren Herstellung und ihre Verwendung als Medikament
EP0427160B1 (de) Benzylselenobenzamide von Aminopyridinen und Picolylaminen
DE69416131T2 (de) Piperidinyl-substituierte methanoanthracene als d1/d2-antagonisten und 5ht2-serotonin-antagonisten
DE2315339A1 (de) N-(heteroarylmethyl)-2'-hydroxy-5.9. 9-trimethyl-benzomorphane, deren saeureadditionssalze, diese enthaltende arzneimittel sowie verfahren zu ihrer herstellung
WO1996022280A1 (de) N-substituierte-1-acylaminoalkyl piperidine zur behandlung von cerebralen störungen und depressionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTRAZENECA UK LTD., LONDON, GB

R071 Expiry of right

Ref document number: 533344

Country of ref document: EP